Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development of therapies for central nervous system disorders.
Needham对Praxis Precision Medicines Inc (NASDAQ:PRAX)，一家从事中枢神经系统疾病治疗方案开发的临床生物制药公司，进行了覆盖。
The company's lead product ulixacaltamide for essential tremor (ET) is undergoing Essential3 Phase 3 program, with topline results expected in the second half of 2024 to support a planned New Drug Application (NDA) submission in 2025.
该公司的首款针对重要震颤病（ET）的主打产品ulixacaltamide正在进行Essential3第三阶段计划，预计在2024年下半年公布最终结果，以支持计划在2025年提交新药申请（NDA）。
- The analyst writes that sales of Ulixa for essential tremor (ET), if successful in Phase 3, could peak at over $1 billion in 2030 (60% probability of success).
- Needham writes, "value of ulixacaltamide in essential tremor alone is underappreciated at current levels."
- 分析师写道，如果Essential3第三阶段成功，针对重要震颤病（ET）的Ulixa的销售额可能在2030年达到10亿美元以上（成功的概率为60%）。
- Needham表示，ulixacaltamide在重要震颤病中的价值在当前水平下被低估。
The analyst initiates with a Buy rating and a price target of $145.
该分析师发起了买入评级，给出了145美元的目标价位。
The company's second program is PRAX-628 for Focal Onset Seizures.
该公司的第二个项目是PRAX-628，针对局灶性发作性癫痫。
- Praxis plans to initiate two efficacy studies in focal onset seizures. The first study is expected to begin in the second half of 2024, with topline results expected in 2025, and the second study is expected to initiate in the first half of 2025, with topline results expected in the first half of 2026.
- Praxis计划启动两项针对局灶性发作性癫痫的有效性研究。第一项研究预计于2024年下半年开始，最终结果预计在2025年公布。第二项研究预计于2025年上半年开始，最终结果预计在2026年上半年公布。
Praxis anticipates topline results from the Phase 2 EMBOLD study of PRAX-562 for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) in the third quarter of 2024.
Praxis预计在2024年第三季度公布PRAX-562治疗SCN2A和SCN8A发育性和癫痫性脑病（DEEs）的II期EMBOLD研究的最终结果。
Praxis is completing multiple global regulatory interactions in the first half of 2024 in anticipation of starting the pivotal phase of the program later in 2024 for Elsunersen (PRAX-222) for SCN2A Gain-of-Function DEEs.
Praxis于2024年上半年完成了多个全球性监管部门的交互，并有望在2024年晚些时候开始该计划的关键阶段，该计划旨在治疗SCN2A增效型DEEs的Elsunersen（PRAX-222）。
PRAX-628 in focal epilepsy and elsunersen in SCN2A GoF could drive more than $1.5 billion in peak sales, with an upside from label expansion.
PRAX-628治疗局灶性癫痫和SCN2A增效型DEEs的Elsunersen可能带来超过15亿美元的销售额，并具有标签扩展的潜力。
Praxis' cash runway into 2027 and an early pipeline across the Cerebrum and Solidus platforms can potentially generate significant long-term value.
Praxis的现金储备可以支持公司运营到2027年，并且具有Cerebrum和Solidus平台上的早期管线，这可能产生显着的长期价值。
Needham adds that positive data from Ulixa Phase 3 and POC for PRAX-562 in the third quarter should continue to drive momentum in Praxis stock.
Needham补充说，第三季度Ulixa第三阶段和PRAX-562 POC的积极数据应继续推动Praxis股票的动力。
Price Action: PRAX shares are down 3.44% at $40.27 at the last check on Monday.
股票价格：截至星期一的最后一次检查，PRAX股价下跌了3.44%，降至40.27美元。
Photo by PublicDomainPictures from Pixabay
图片由Pixabay的PublicDomainPictures提供